Home › Research › Topics › repurposing
repurposing
234 studies tagged repurposing, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
- Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
- DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18
Studies
234 studies carry this tag.
Date range
1977 to 2026
Top journals
- Research Square 9
- Journal of medicinal chemistry 7
- International journal of molecular sciences 6
- Journal of Alzheimer's disease : JAD 6
- Nature reviews. Drug discovery 6
154 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Sulforaphane (SFN), a natural isothiocyanate from cruciferous vegetables, exerts neuroprotective effects through mechanisms extending beyond canonical Nrf2/ARE activation.
-
Alzheimer's disease continues to be one of the major critical neurodegenerative ailments of the modern era, with acetylcholinesterase (AChE) inhibition standing as a foundational therapeutic strategy.
-
NOS1AP is an adaptor for neuronal nitric oxide synthase that engages several partner proteins and is implicated in Alzheimer’s disease.
-
Alzheimer's Disease (AD), the most common neurodegenerative disease in the world, is caused by a variety of factors that lead to neuronal injury and an alteration in neurotransmitter production and release.
-
Alzheimer’s Disease (AD) is characterised by the progressive depletion of Acetylcholine (ACh), a neurotransmitter essential for cognition and synaptic communication.
-
Mercury remains a pervasive environmental neurotoxicant strongly implicated in hippocampal oxidative injury and dementia-related cognitive decline, yet safe multi-target agents against its neurotoxicity remain limited.
-
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia in older people.
-
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and cholinergic dysfunction [1].
-
Neurotrophins regulate neuronal survival, differentiation, and synaptic plasticity through activation of tropomyosin receptor kinase (Trk) receptors, and their dysregulation is strongly implicated in neurodegenerative disorders, including Alzheimer’s disease.
-
Galantamine is a pharmaceutically relevant Amaryllidaceae alkaloid used for the treatment of Alzheimer’s disease.
-
Coumarins playing multiple roles in the life of plants also exhibit a wide range of positive effects for human health.
-
Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are central regulators of synaptic homeostasis, plasticity, and dysfunction during Alzheimer’s disease (AD) progression.
-
Alzheimer’s disease (AD) represents a progressively growing worldwide public health burden.
-
Alzheimer's disease (AD) remains one of the most devastating and economically costly neurological conditions of the modern era, affecting over 55 million individuals worldwide with no approved disease-modifying therapy.
-
Alzheimer's disease is a progressive neurodegenerative disorder affecting over 55 million people worldwide, with no disease-modifying treatments currently approved.
-
In total, 45 constituents were mapped to 181 human target genes through measured compound-target edges.
-
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and there are still no strategies to slow or prevent its clinical progression.
-
Pharmacological interventions for dementia include medications aimed at alleviating its core symptom: cognitive dysfunction.
-
With this notice, the Internation Journal of Molecular Sciences Editorial Office states their awareness of the concerns regarding the integrity of a number of the figures published within this publication [...].
-
Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD).
-
43/100
Seizures in people with Alzheimer's disease are increasingly recognized to worsen disease burden and accelerate functional decline.
-
Microglial phagocytosis is a highly energy-consuming process that plays critical roles in clearing neurotoxic amyloid-β (Aβ) in Alzheimer's disease (AD).
-
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60.
-
Medical science has made revolutionary discoveries around the nosology and aetiology of the neurodegenerative diseases.
-
Drug repurposing, also known as drug repositioning, involves identifying new applications for drugs whose effects in a disease are already established.
-
Behavioral analyses on APP/PS1 mice demonstrated that Semaglutide improved the cognitive capabilities, particularly in the learning and memory domains.
-
The prevalence of neurocognitive disorders (NCD) increases every year as the population continues to age, leading to significant global health concerns.
-
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges.
-
The patent introduces a class of agents that target amyloid aggregation, and subsequently, reduce amyloid β-oligomer neurotoxicity.
-
Neurodegenerative diseases (NDDs) are neuronal problems that include the brain and spinal cord and result in loss of sensory and motor dysfunction.
-
A new class of compounds, namely highly substituted diaminocyclopentane-l-lysine adducts, have been discovered as potent inhibitors of O-GlcNAcase, an enzyme crucial for protein de-O-glycosylation.
-
Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases.
-
Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time, exerting a significant impact on physical and mental health and leading to death.
-
Drug repurposing, also referred to as drug repositioning or drug reprofiling, is a scientific approach to the detection of any new application for an already approved or investigational drug.
-
TTSs present some limit factors in terms of absorption due to skin physiology and the size of the molecules with established limits of percutaneous penetration (molecular mass of 500 g/mol and log P of 5).
-
We find that IRAs can cross the BBB by two separate processes; one that is fast and one that is slow.
-
Huntington's Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities.
-
Neurodegenerative processes characterizing Alzheimer's disease (AD) are strictly related to the impairment of cholinergic and glutamatergic neurotransmitter systems which provoke synaptic loss.
-
Alzheimer's disease (AD) is a progressive age-related neurodegenerative brain disorder, which leads to loss of memory and other cognitive dysfunction.
-
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of cognitive decline.
-
Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disease associated with aging.
-
A new class of compounds inhibiting de-O-glycosylation of proteins has been identified.
-
Alzheimer's disease (AD) is the most common chronic neurodegenerative disease worldwide.
-
Alzheimer's disease (AD), the leading cause of dementia, is a growing health issue with very limited treatment options.
-
We identified glutaminase as a promising drug target.
-
Organophosphorus nerve agents pose a global threat to both military personnel and civilian population, because of their high acute toxicity and insufficient medical countermeasures.
-
Lower activity of the histaminergic system is associated with neurological disorders, including Alzheimer's disease (AD).
-
Drugs like Zileuton, Salbutamol, Baricitinib, Carmustine, Paclitaxel, and Nilotinib were observed to be involved in regulation of neurotransmitters.
-
Alzheimer's disease (AD) is a multivariate and diversified disease and affects the most sensitive areas of the brain, the cerebral cortex, and the hippocampus.
-
Reversal genes and the candidate compounds were identified by the leave-one-out cross-validation procedure.
From across this tag
7 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity
- Identification of novel functional inhibitors of acid sphingomyelinase
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial
- Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics
- Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
- BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease
- Discovering new treatments for Alzheimer's disease by repurposing approved medications